Comparison of Absolute Expression and Turnover Number of COX-1 and COX-2 in Human and Rodent Cells and Tissues

References

• Wang D, DuBois RN. PPARdelta and PGE2 signaling pathways communicate and connect inflammation to colorectal cancer. Inflamm Cell Signal. 2014;1:874.
   Google Scholar
• Mohammadi A, Yaghoobi MM, Gholamhoseinian Najar A, Kalantari-Khandani B, Sharifi H, Saravani M. HSP90 Inhibition Suppresses PGE2 Production via Modulating COX-2 and 15-PGDH Expression in HT-29 Colorectal Cancer Cells. Inflammation. 2016;39:1116–1123.
   PubMed Web of Science ®Google Scholar
• Echizen K, Hirose O, Maeda Y, Oshima M. Inflammation in gastric cancer: interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways. Cancer Sci. 2016;107:391–397.
   PubMed Web of Science ®Google Scholar
• Zidar N, Odar K, Glavac D, Jerse M, Zupanc T, Stajer D. Cyclooxygenase in normal human tissues–is COX‐1 really a constitutive isoform, and COX‐2 an inducible isoform? J Cell Mol Med. 2009;13:3753–3763.
   PubMed Web of Science ®Google Scholar
• Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res. 2009;50:S423–S428.
   PubMed Web of Science ®Google Scholar
• Patrono C, Patrignani P, Rodríguez LAG. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108:7–13.
   PubMed Web of Science ®Google Scholar
• Stenson WF. Prostaglandins and epithelial response to injury. Curr Opin Gastroenterol. 2007;23:107–110.
   PubMed Web of Science ®Google Scholar
• Kämpfer H, Schmidt R, Geisslinger G, Pfeilschifter J, Frank S. Wound inflammation in diabetic ob/ob mice: functional coupling of prostaglandin biosynthesis to cyclooxygenase-1 activity in diabetes-impaired wound healing. Diabetes. 2005;54:1543–1551.
   PubMed Web of Science ®Google Scholar
• Shukla SK, Sharma AK, Gupta V, Yashavarddhan M. Pharmacological control of inflammation in wound healing. J Tissue Viability. 2019;28:218–222.
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010;29:781–788.
   PubMed Web of Science ®Google Scholar
• Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996;97:2672–2679.
   PubMed Web of Science ®Google Scholar
• Ma Y, Li H, Yue Z, et al. Cryptotanshinone attenuates cardiac fibrosis via downregulation of COX-2, NOX-2, and NOX-4. J Cardiovasc Pharmacol. 2014;64:28–37.
   PubMed Web of Science ®Google Scholar
• Fujita T, Matsui M, Takaku K, et al. Size-and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. 1998;58:4823–4826.
   PubMed Web of Science ®Google Scholar
• Hotz-Behofsits C, Walley M, Simpson R, Bjarnason I. COX-1, COX-2 and the topical effect in NSAID-induced enteropathy. Inflammopharmacology. 2003;11:363–370.
   PubMedGoogle Scholar
• Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674–1682.
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Eng J Med. 2006;355:873–884.
   PubMed Web of Science ®Google Scholar
• Amos-Landgraf JM, Kwong LN, Kendziorski CM, et al. A target-selected APC-mutant rat kindred enhances the modeling of familial human colon cancer. Proc Natl Acad Sci U S A. 2007;104:4036–4041.
   PubMed Web of Science ®Google Scholar
• Yun C, Dashwood W-M, Kwong LN, et al. Accurate quantification of PGE2 in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC–MS/MS. J Pharm Biomed Anal. 2018;148:42–50.
   PubMed Web of Science ®Google Scholar
• Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Safety. 2006;29:621–632.
   PubMed Web of Science ®Google Scholar
• Trepanier CH, Milgram NW. Neuroinflammation in Alzheimer’s disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy? J Alzheimer’s Dis. 2010;21:1089–1099.
   PubMed Web of Science ®Google Scholar
• Adelizzi RA. COX-1 and COX-2 in health and disease. J Am Osteopath Assoc. 1999;99:S7–12.
   Google Scholar
• Vanhoutte PM. COX-1 and vascular disease. Clin Pharmacol Ther. 2009;86:212–215.
   PubMed Web of Science ®Google Scholar
• Jensen TSR, Mahmood B, Damm MB, et al. Combined activity of COX-1 and COX-2 is increased in non-neoplastic colonic mucosa from colorectal neoplasia patients. BMC Gastroenterol. 2018;18:1–10.
   PubMed Web of Science ®Google Scholar
• Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986–1000.
   PubMed Web of Science ®Google Scholar
• Jang Y, Kim M, Hwang SW. Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception. J Neuroinflammation. 2020;17:30.
   PubMed Web of Science ®Google Scholar
• Kitamura T, Kawamori T, Uchiya N, et al. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis. 2002;23:1463–1466.
   PubMed Web of Science ®Google Scholar
• Long S, Theiss KL, Mattei A, Loftin CD, Li T. Solid-State Properties of the Cyclooxygenase-1-Selective Inhibitor, SC-560. Aaps Pharmscitech. 2010;11:485–488.
   PubMed Web of Science ®Google Scholar
• Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest. 2011;121:132–147.
   PubMed Web of Science ®Google Scholar
• Dong G, Chen H, Shi Y, Jiang C, Yang H. MicroRNA-758 Regulates Oral Squamous Cell Carcinoma via COX-2. Indian J Surgery. 2020;1–7.
   PubMed Web of Science ®Google Scholar
• Hsu J-L, Chen S-H. Stable isotope dimethyl labelling for quantitative proteomics and beyond. Philosophical Transactions Royal Soc. 2016;374:20150364.
   PubMed Web of Science ®Google Scholar
• Chen G, Pramanik BN. Application of LC/MS to proteomics studies: current status and future prospects. Drug Discov Today. 2009;14:465–471.
   PubMed Web of Science ®Google Scholar
• Fallon JK, Harbourt DE, Maleki SH, Kessler FK, Ritter JK, Smith PC. Absolute quantification of human uridine-diphosphate glucuronosyl transferase (UGT) enzyme isoforms 1A1 and 1A6 by tandem LC-MS. Drug Metab Lett. 2008;2:210–222.
   PubMedGoogle Scholar
• Xu B, Gao S, Wu B, Yin T, Hu M. Absolute quantification of UGT1A1 in various tissues and cell lines using isotope label-free UPLC–MS/MS method determines its turnover number and correlates with its glucuronidation activities. J Pharm Biomed Anal. 2014;88:180–190.
   PubMed Web of Science ®Google Scholar
• Meng F, Zou L, Zhang T, et al. Using LC–MS/MS-based targeted proteomics to monitor the pattern of ABC transporters expression in the development of drug resistance. Cancer Manag Res. 2018;10:2859.
   PubMed Web of Science ®Google Scholar
• Ranelletti FO, Almadori G, Rocca B, et al. Prognostic significance of cyclooxygenase‐2 in laryngeal squamous cell carcinoma. Int j Cancer. 2001;95:343–349.
   PubMed Web of Science ®Google Scholar
• Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55–80.
   PubMed Web of Science ®Google Scholar
• Bui D, Li L, Yin T, et al. Pharmacokinetic and Metabolic Profiling of Key Active Components of Dietary Supplement Magnolia officinalis Extract for Prevention against Oral Carcinoma. J Agric Food Chem. 2020;68:6576–6587.
   PubMed Web of Science ®Google Scholar
• Chen J, Zheng H, Zeng S, et al. Profiles and Gender-Specifics of UDP-Glucuronosyltransferases and Sulfotransferases Expressions in the Major Metabolic Organs of Wild-Type and Efflux Transporter Knockout FVB Mice. Mol Pharm. 2017;14:2967–2976.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang L, Xie L, et al. Design and Synthesis of a Novel NIR Celecoxib-Based Fluorescent Probe for Cyclooxygenase-2 Targeted Bioimaging in Tumor Cells. Molecules. 2020;1:25.
   Google Scholar
• Resta D, Brambilla F, Arnoldi A. HPLC-Chip-Multiple Reaction Monitoring (MRM) method for the label-free absolute quantification of γ-conglutin in lupin: proteotypic peptides and standard addition method. Food Chem. 2012;131:126–133.
   Web of Science ®Google Scholar
• Femia AP, Soares PV, Luceri C, Lodovici M, Giannini A, Caderni G. Sulindac, 3, 3’-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an APC-driven model of colon carcinogenesis. BMC Cancer. 2015;15:1–9.
   PubMed Web of Science ®Google Scholar
• Gu M, Nishihara R, Chen Y, et al. Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. Oncotarget. 2017;8:87379–87389.
   PubMedGoogle Scholar
• Yun C, Dashwood W-M, Li L, et al. Acute changes in colonic PGE 2 levels as a biomarker of efficacy after treatment of the Pirc (F344/NTac-APC am1137) rat with celecoxib. Inflammation Res. 2020;69:131–137.
   PubMed Web of Science ®Google Scholar
• Loftin CD, Tiano HF, Langenbach R. Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002;68:177–185.
   PubMed Web of Science ®Google Scholar
• Fairweather M, Heit YI, Buie J, et al. Celecoxib inhibits early cutaneous wound healing. J Surg Res. 2015;194:717–724.
   PubMed Web of Science ®Google Scholar
• Gilman KE, Limesand KH. The complex role of prostaglandin E2-EP receptor signaling in wound healing. Am J Physiol Regul Integr Comp Physiol. 2021;320:R287–R296.
   PubMed Web of Science ®Google Scholar
• Bustin SA, Nolan T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech. 2004;15:155.
   PubMedGoogle Scholar